Ultragenyx Pharmaceutical (RARE) Competitors

Moderna (NASDAQ:MRNA) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Is MRNA or RARE more profitable?

Ultragenyx Pharmaceutical has a net margin of -87.34% compared to Moderna's net margin of -94.31%. Moderna's return on equity of -25.96% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-94.31%	-25.96%	-20.09%
Ultragenyx Pharmaceutical	-87.34%	-237.48%	-37.66%

Do insiders & institutionals hold more shares of MRNA or RARE?

75.3% of Moderna shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 11.0% of Moderna shares are held by company insiders. Comparatively, 5.5% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has more volatility and risk, MRNA or RARE?

Moderna has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500.

Which has preferable valuation and earnings, MRNA or RARE?

Ultragenyx Pharmaceutical has lower revenue, but higher earnings than Moderna. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$3.24B	3.23	-$3.56B	-$7.53	-3.57
Ultragenyx Pharmaceutical	$560.23M	4.98	-$569.18M	-$5.53	-5.24

Does the media prefer MRNA or RARE?

In the previous week, Ultragenyx Pharmaceutical had 35 more articles in the media than Moderna. MarketBeat recorded 52 mentions for Ultragenyx Pharmaceutical and 17 mentions for Moderna. Moderna's average media sentiment score of 0.22 beat Ultragenyx Pharmaceutical's score of 0.16 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
Ultragenyx Pharmaceutical	12 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Do analysts prefer MRNA or RARE?

Moderna currently has a consensus price target of $43.59, indicating a potential upside of 62.10%. Ultragenyx Pharmaceutical has a consensus price target of $81.50, indicating a potential upside of 181.33%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	4 Sell rating(s)	16 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.04
Ultragenyx Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.92

Summary

Ultragenyx Pharmaceutical beats Moderna on 9 of the 17 factors compared between the two stocks.